New hope for rare liver disease: major trial tests potential treatment
NCT ID NCT07387549
Summary
This study aims to see if a daily pill called elafibranor can slow down a rare, serious liver disease called Primary Sclerosing Cholangitis (PSC). About 350 adults with PSC will be randomly assigned to take either elafibranor or a placebo (inactive pill) for several years. Researchers will track whether the medicine helps delay serious liver problems, improves symptoms like itching and fatigue, and is safe for long-term use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.